

25 January 2017

Japanese Patent Office grants skin delivery patent

OBJ Limited (ASX: OBJ) is pleased to report it has received notice from its Patent Attorney that the Japanese Patent Office (JPO) has now issued the Deed of Letters Patent for the granting of the magnetic microarray patent to OBJ.

The Certificate of Patent, number 6046609 titled ‘Delivery of Skincare Products’ provides OBJ and its licensees with the patent protection in Japan for its magnetic microarray technology in skin delivery applications, already licensed for the beauty and grooming market sector. The patent is effective from 25 November 2016 and will expire on 17 June 2031.

The company announced the acceptance of this patent by the JPO on 28 November 2016. While the granting of this patent is normally a formality, the granting of a Japanese patent is viewed by the Company as a major step forward. The granting of the same patent by the US Patent Office was announced on 12 October 2016, while prosecution of the same patent family is continuing in Europe.

As with the patent granted by the USA Patent Office, the Japanese patent has a life of 20 years from the earliest filing date of the application and will be of great interest and value to SK-II, the Japanese based brand currently commercialising OBJ’s microarray technology. Other Asia-based potential partners to OBJ will also benefit from this patent protection.

“Intellectual property protection is a critical activity for the company,” said Jeffery Edwards, the company’s Managing Director.

“We endeavour to achieve the widest possible protection, especially in mature and sophisticated markets such as Japan, USA and Europe, where patent rights are strongly enforced by Governments.”

This new patent further expands OBJ’s growing portfolio of granted intellectual property protection.

About OBJ

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

Directors

Mr Glyn Denison
Mr Jeffrey Edwards
Dr Chris Quirk

Company Secretary

Mr John Palermo

Registered Office:

284 Oxford Street
Leederville
Western Australia 6007
Tel: +61 8 9443 3011
Fax: +61 8 9443 9960
www.obj.com.au
ABN: 72 056 482 636

25 January 2017

About OBJ's Technologies

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration through the skin of drugs, active ingredients and formulations at the molecular level.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ develops low cost micro-array film technology that utilise diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

Forward-looking Statements

This announcement contains certain “forward-looking statements” concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

For more information:

Matthew Wright

matt@nwrcommunications.com.au

Phone: +61 451 896 420

Directors

Mr Glyn Denison
Mr Jeffrey Edwards
Dr Chris Quirk

Company Secretary

Mr John Palermo

Registered Office:

284 Oxford Street
Leederville
Western Australia 6007
Tel: +61 8 9443 3011
Fax: +61 8 9443 9960
www.obj.com.au
ABN: 72 056 482 636